NYSEAMERICAN:NSPR

InspireMD Stock Forecast, Price & News

$4.06

-0.27 (-6.24 %)

(As of 07/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.88

▼

$4.35

50-Day Range

$4.83

▼

$6.60

52-Week Range

$3.88

▼

$22.20

Volume544,950 shs

Average Volume916,797 shs

Market Capitalization$32.10 million

P/E RatioN/A

Dividend YieldN/A

Beta1.83

30 days | 90 days | 365 days | Advanced Chart

Receive NSPR News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.

Form 8-K InspireMD, Inc. For: Jul 26 - StreetInsider.com
July 26, 2021 | streetinsider.com

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS - Yahoo Finance
July 23, 2021 | finance.yahoo.com

InspireMD Enrolls and Treats First Patients at Ballad Health System in US Registration C-Guardian Clinical Trial of CGuard EPS - GlobeNewswire
July 23, 2021 | globenewswire.com

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
July 23, 2021 | finance.yahoo.com

Ballad Health hosts first United States clinical trials of CGuard Embolic Protection System - GlobeNewswire
July 22, 2021 | globenewswire.com

38 Stocks Moving In Wednesday's Mid-Day Session Benzinga - Benzinga
July 21, 2021 | benzinga.com

InspireMD Sees Unusually High Options Volume (NYSEAMERICAN:NSPR)
July 21, 2021 | americanbankingnews.com

Short Interest in InspireMD, Inc. (NYSEAMERICAN:NSPR) Decreases By 30.3%
July 2, 2021 | americanbankingnews.com

InspireMD, Inc. (NSPR)
June 18, 2021 | finance.yahoo.com

Should I Avoid InspireMD Inc (NSPR)? - Yahoo Finance
June 13, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NSPR
Previous SymbolNASDAQ:NSPR
CUSIPN/A
CIK1433607
Webwww.inspiremd.com
Phone+1-857-4536553
Employees45
Year FoundedN/A

Sales & Book Value

Annual Sales$2.48 million
Price / Sales12.94
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.00 per share
Price / Book2.03

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares7,906,000
Market Cap$32.10 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

1067th out of 4,434 stocks

Surgical & Medical Instruments Industry

93rd out of 362 stocks

3.5 Analyst's Opinion

Consensus Rating
InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, InspireMD has a forecasted upside of 158.6% from its current price of $4.06.
Amount of Analyst Coverage
InspireMD has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
InspireMD has received 196 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
InspireMD has received 187 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
InspireMD has received 51.17% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote “Outperform” if you believe NSPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
InspireMD does not currently pay a dividend.
Dividend Growth
InspireMD does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InspireMD insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of InspireMD is held by insiders.
Percentage Held by Institutions
88.67% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of InspireMD is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InspireMD is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InspireMD has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

InspireMD (NYSEAMERICAN:NSPR) Frequently Asked Questions

Is InspireMD a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" InspireMD stock.
View analyst ratings for InspireMD or view top-rated stocks.

What stocks does MarketBeat like better than InspireMD?

Wall Street analysts have given InspireMD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InspireMD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InspireMD?

InspireMD saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 106,200 shares, a decrease of 30.3% from the May 31st total of 152,300 shares. Based on an average daily volume of 463,000 shares, the short-interest ratio is currently 0.2 days. Currently, 1.4% of the shares of the stock are sold short.
View InspireMD's Short Interest.

When is InspireMD's next earnings date?

InspireMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for InspireMD.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSEAMERICAN:NSPR) issued its quarterly earnings results on Tuesday, May, 11th. The medical equipment provider reported ($0.53) EPS for the quarter, topping the Zacks' consensus estimate of ($0.60) by $0.07. The medical equipment provider earned $1.01 million during the quarter. InspireMD had a negative net margin of 480.63% and a negative trailing twelve-month return on equity of 58.60%.
View InspireMD's earnings history.

When did InspireMD's stock split? How did InspireMD's stock split work?

Shares of InspireMD reverse split before market open on Tuesday, April 27th 2021. The 1-15 reverse split was announced on Wednesday, April 14th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 26th 2021. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for NSPR?

1 equities research analysts have issued 12-month target prices for InspireMD's shares. Their forecasts range from $10.50 to $10.50. On average, they expect InspireMD's share price to reach $10.50 in the next year. This suggests a possible upside of 158.6% from the stock's current price.
View analysts' price targets for InspireMD or view top-rated stocks among Wall Street analysts.

Who are InspireMD's key executives?

InspireMD's management team includes the following people:

Mr. Marvin L. Slosman, Pres, CEO & Director (Age 56, Pay $526.98k)
Mr. Craig Shore, CFO, Chief Admin. Officer, Sec. & Treasurer (Age 60, Pay $525.32k)
Mr. Roei Samuri, VP of Operations
Mr. Andrea Tommasoli, Sr. VP of Global Sales & Marketing
Mr. Amir Kohen, VP of Fin. & International HR
Dr. Sol J. Barer, Special Advisor to the Board (Age 74)

Who are some of InspireMD's key competitors?

Some companies that are related to InspireMD include Liquidia (LQDA), PolyPid (PYPD), Venus Concept (VERO), Pro-Dex (PDEX), Assure (ARHH), Isoray (ISR), Nephros (NEPH), Avinger (AVGR), Femasys (FEMY), Lyra Therapeutics (LYRA), AIT Therapeutics (AITB), LENSAR (LNSR), Aethlon Medical (AEMD), Spectral Medical (EDTXF) and Nephros (NEPHD).
View all of NSPR's competitors.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Palatin Technologies (PTN), Biocept (BIOC), TransEnterix (TRXC), Catalyst Pharmaceuticals (CPRX), Curis (CRIS), iBio (IBIO), Inovio Pharmaceuticals (INO), Verastem (VSTM), AVEO Pharmaceuticals (AVEO) and Inpixon (INPX).

What is InspireMD's stock symbol?

InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."

How do I buy shares of InspireMD?

Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InspireMD's stock price today?

One share of NSPR stock can currently be purchased for approximately $4.06.

How much money does InspireMD make?

InspireMD has a market capitalization of $32.10 million and generates $2.48 million in revenue each year.

How many employees does InspireMD have?

InspireMD employs 45 workers across the globe.

What is InspireMD's official website?

The official website for InspireMD is www.inspiremd.com.

Where are InspireMD's headquarters?

InspireMD is headquartered at 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel.

How can I contact InspireMD?

InspireMD's mailing address is 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel. The medical equipment provider can be reached via phone at +1-857-4536553 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here